Research study Program year 2025 Source: CMS Open Payments

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation

Research payments

$9,828,065

235 payments

Through program year 2025, $9,828,065 in research payments was reported against A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation, across 235 payments, paid by Vertex Pharmaceuticals Incorporated.

Paid by: Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov: No trial number was reported for this study

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$6,610	2
2024	Research	$655,802	60
2023	Research	$2,583,771	68
2022	Research	$6,389,503	66
2021	Research	$192,378	39

Breakdown

Who paid Research payments · program years 2021–2025

Vertex Pharmaceuticals Incorporated $9,828,065 235 payments

Who received the money Research payments · program years 2021–2025

Massachusetts General Hospital Teaching hospital · MA $479,648 2 payments
The University Of Texas Southwestern Medical Center Organisation paid for research $425,101 3 payments
Childrens Hospital Corporation Teaching hospital · MA $374,984 4 payments
Indiana University Organisation paid for research $299,762 4 payments
Northwell Health Long Island Jewish Medical Center Organisation paid for research $278,633 4 payments
Banner University Of Arizona Medical Center Organisation paid for research $267,098 3 payments
Alfred I Dupont Hosp For Children Teaching hospital · DE $256,635 6 payments
Columbia University Medical Center Cf Organisation paid for research $239,360 3 payments
Morristown Medical Center Teaching hospital · NJ $224,693 4 payments
Northwestern Memorial Hospital Organisation paid for research $223,080 3 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

10 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.

Cite this record

“A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation”, Who Paid My Doc, citing CMS Open Payments, program year 2025. https://www.whopaidmydoc.com/research-studies/a-phase-3-randomized-double-blind-controlled-study-evaluating-the-efficacy-and-safety-of-vx-121-combination-therapy-in-subjects-with-cystic-fibrosis-who-are-homozygous-for-f508del-heterozygous-for-f508del-and-a-gating-f-g-or-residual-function-f-rf-mutation-or-have-at-least-1-other-triple-combination-responsive-cftr-mutation-and-no-f508del-mutation-59799815

Figures here may be reproduced with attribution and a link — see for journalists and researchers.